Many at-risk Americans either do not know about PrEP or don't have access. Here's why raising awareness is key to ending the ...

A new study shows low rates of pre-exposure prophylaxis (PrEP) prescribing to sexual and gender minority individuals living ...

New data demonstrated that long-acting cabotegravir was preferable to daily dolutegravir/lamivudine in treatment-naive people living with HIV.

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention as a tool ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.

As Black women are being hit with new HIV cases, stars such as Tamar Braxton is unapologetically shining a light on HIV ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Chicago, Cook County and Illinois are on the cusp of ending the HIV epidemic in our city, county and state. But that progress ...

Increasing the use of Apretude among Black women requires not only expanding awareness of the long-acting PrEP regimen in ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...